Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia

Xiaoxiao Lu1 Real World Value and Evidence, Oncology, Janssen Scientific Affairs, LLC, Horsham, PA, USAView further author information

Bruno Emond2 Health Economics and Outcomes Research, Analysis Group, Inc, Montréal, Québec, CanadaCorrespondence[email protected]

Laura Morrison2 Health Economics and Outcomes Research, Analysis Group, Inc, Montréal, Québec, CanadaView further author information

Frederic Kinkead2 Health Economics and Outcomes Research, Analysis Group, Inc, Montréal, Québec, CanadaView further author information

Patrick Lefebvre2 Health Economics and Outcomes Research, Analysis Group, Inc, Montréal, Québec, CanadaView further author information

Marie-Hélène Lafeuille2 Health Economics and Outcomes Research, Analysis Group, Inc, Montréal, Québec, CanadaView further author information

Wasiulla Khan1 Real World Value and Evidence, Oncology, Janssen Scientific Affairs, LLC, Horsham, PA, USAView further author information

Linda H Wu1 Real World Value and Evidence, Oncology, Janssen Scientific Affairs, LLC, Horsham, PA, USAView further author information

Zaina P Qureshi1 Real World Value and Evidence, Oncology, Janssen Scientific Affairs, LLC, Horsham, PA, USAView further author information

Ryan Jacobs3 Hematology and Medical Oncology, Atrium Health Levine Cancer Institute, Charlotte, NC, USAView further author information

Your download is now in progress and you may close this window